

Malawi

Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Malawi															
2. Vaccine grant number:	1114-MWI-12C-X, 1516-MWI-12c-X, 17-MWI-12c-X, 17-MWI-25a-Y, 17-MWI-25a-Y, 1820-MWI-12d-X															
3. Date of Decision Letter:	10 September 2019															
4. Date of the Partnership Framework Agreement:	29 October 2013															
5. Programme title:	New Vaccine Support (NVS), Pneumococcal , Routine															
6. Vaccine type:	Pneumococcal															
7. Requested product presentation and formulation of vaccine:	PCV13, 4 dose(s) per vial, LIQUID															
8. Programme Duration:¹	2011-2020															
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)															
	2011-2018	2019	2020	2021	2022	2023	Total ²									
Programme Budget (US\$)	67,869,522	5,714,500	6,839,000	-	-	-	80,423,022									
10. Vaccine introduction grant	Not applicable															
11. Product switch grant	<table border="1" style="width: 100%; border-collapse: collapse; margin: 10px auto;"> <thead> <tr> <th colspan="3" style="text-align: center;">Approval</th> </tr> <tr> <th style="text-align: center;">Year</th> <th style="text-align: center;">Grant Number</th> <th style="text-align: center;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2017</td> <td style="text-align: center;">17-MWI-25a-Y</td> <td style="text-align: right;">182,289</td> </tr> </tbody> </table>							Approval			Year	Grant Number	Amount (US\$)	2017	17-MWI-25a-Y	182,289
Approval																
Year	Grant Number	Amount (US\$)														
2017	17-MWI-25a-Y	182,289														
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)															
	2011-2018						2019									
Number of vaccine doses							1,699,800									
Annual Amounts (US\$)	67,869,522						5,714,500									
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.															

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019
Number of vaccine doses	122,200
Number of AD syringes	-
Number of re-constitution syringes	-
Number of safety boxes	-
Value of vaccine doses (US\$)	359,984
Total co-financing payments (US\$) (including freight)	364,500

16. Operational support for catch-up campaigns:

Not applicable

17. Additional Reporting Requirements:

	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 15 May</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

Signed by,

On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
10 September 2019